Drug Trial Radar · NCT03198507
ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
Last checked: Nov 19, 2026Latest source record: Mar 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
455
Actual
Start
Jun 18, 2017
Primary completion
Oct 24, 2018
Study completion Dec 13, 2018
Sponsor
- Lead sponsor
- RedHill Biopharma LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jun 26, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The "test and treat" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H. pylori infection in dyspeptic patients against an active comparator.
Conditions
- Helicobacter Pylori Infection
- Dyspepsia
Interventions
RHB-105Drug
The intended dose of RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, is equivalent to a total daily dose of: * Rifabutin 150 mg * Amoxicillin 3000 mg * Omeprazole 120 mg One 50mg Riboflavin tablet to be taken once daily to maintain the blind.
Active ComparatorDrug
The intended dose of the Active Comparator (250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of: * Amoxicillin 3000 mg * Omeprazole 120 mg One 50mg Riboflavin tablet to be taken once daily to maintain the blind.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Eradication of H. PyloriTime frame: 43-71 days after initiation of treatment
Locations
55 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Dothan, Alabama
Research Site
Phoenix, Arizona
Research Site
Tucson, Arizona
Research Site
North Little Rock, Arkansas
Research Site
Anaheim, California
Research Site
Chula Vista, California
Research Site
Lomita, California
Research site
San Carlos, California
Research Site
Bristol, Connecticut
Research Site
Aventura, Florida
Research Site
Clearwater, Florida
Research Site
Coral Springs, Florida
Research Site
Homestead, Florida
Research Site
Jacksonville, Florida
Research Site
Lauderdale Lakes, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Orange City, Florida
Research Site
Palm Harbor, Florida
Research Site
Athens, Georgia
Research Site
Macon, Georgia
Research Site
Marietta, Georgia
Research Site
Elwood, Indiana
Research Site
Metairie, Louisiana
Research Site
Shreveport, Louisiana
Research Site
Baltimore, Maryland
Research Site
Chevy Chase, Maryland
Research Site
Brockton, Massachusetts
Research Site
Chesterfield, Missouri
Research Site
Wyoming, Missouri
Research Site
Las Vegas, Nevada
Research Site
Las Vegas, Nevada
Research Site
Great Neck, New York
Research Site
Concord, North Carolina
Research Site
Davidson, North Carolina
Research Site
Fayetteville, North Carolina
Research Site
Greenville, North Carolina
Research Site
Tulsa, Oklahoma
Research Site
Greenville, South Carolina
Research Site
Sioux Falls, South Dakota
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.